MyFinsight
Home
Blog
About
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$49,000K
Free Cash flow
-$98,000K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Proceeds from sale of marketable...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Accounts receivable
Purchase of marketable securitie...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-92,000
-185,000
-128,556
-180,413
Stock-based compensation
34,000
30,000
37,289
37,265
Amortization of discount on marketable securities, net
0
1,000
516
704
Depreciation and amortization
8,000
8,000
8,785
8,606
Non-cash royalty revenue
35,000
20,000
37,581
24,911
Non-cash interest expense on liabilities for sales of future royalties
22,000
21,000
19,469
14,148
Other
5,000
-1,000
-693
273
Accounts receivable
62,000
-19,000
33,834
-5,425
Inventory
3,000
4,000
-150
5,595
Prepaid expenses and other assets
-12,000
9,000
2,740
-9,905
Accounts payable, accrued, and other liabilities
24,000
-57,000
37,012
45,124
Net cash used in operating activities
-97,000
-197,000
-99,829
-91,423
Purchase of property, plant, and equipment
1,000
1,000
938
1,278
Purchase of marketable securities
57,000
131,000
153,555
16,942
Proceeds from sale of marketable securities
38,000
-
-143
0
Proceeds from maturities of marketable securities
67,000
88,000
82,116
135,587
Payments for intangible asset
0
5,000
0
0
Other
3,000
0
-273
185
Net cash (used in) provided by investing activities
44,000
-49,000
-72,247
117,182
Proceeds from the sale of future royalties, net
-
-
392,000
-
Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net
-
-
0
0
Proceeds from the issuance of common stock in connection with at-the-market offering, net
0
-
272
0
Proceeds from the issuance of common stock under equity plan awards, net of tax
-
-
-
-2
Proceeds from the issuance of common stock under equity plans, net
3,000
-
6,000
-
Proceeds from issuance of equity from noncontrolling interest
-
-
0
0
Other
-
-
0
-
Net cash provided by financing activities
3,000
-
394,192
2
Effect of exchange rate changes on cash
1,000
-1,000
-656
294
Net (decrease) increase in cash, cash equivalents and restricted cash
-49,000
-247,000
221,460
26,055
Cash, cash equivalents and restricted cash at beginning of period
189,000
436,000
214,699
184,159
Cash, cash equivalents and restricted cash at end of period
140,000
189,000
436,000
214,699
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$67,000K
(-70.39%↓ Y/Y)
Proceeds from the
issuance of common stock...
$3,000K
Proceeds from sale of
marketable securities
$38,000K
(26473.43%↑ Y/Y)
Net cash (used in)
provided by investing...
$44,000K
(-76.97%↓ Y/Y)
Net cash provided by
financing activities
$3,000K
(-96.42%↓ Y/Y)
Effect of exchange rate
changes on cash
$1,000K
(-77.07%↓ Y/Y)
Canceled cashflow
$61,000K
Net (decrease)
increase in cash, cash...
-$49,000K
(-1192.53%↓ Y/Y)
Canceled cashflow
$48,000K
Stock-based compensation
$34,000K
(-56.66%↓ Y/Y)
Accounts payable,
accrued, and other...
$24,000K
(141.28%↑ Y/Y)
Non-cash interest
expense on liabilities...
$22,000K
(-22.49%↓ Y/Y)
Prepaid expenses and
other assets
-$12,000K
(-169.91%↓ Y/Y)
Depreciation and
amortization
$8,000K
(-54.57%↓ Y/Y)
Purchase of marketable
securities
$57,000K
(267.67%↑ Y/Y)
Other
$3,000K
(175.74%↑ Y/Y)
Purchase of property,
plant, and equipment
$1,000K
(-73.57%↓ Y/Y)
Net cash used in
operating activities
-$97,000K
(64.69%↑ Y/Y)
Canceled cashflow
$100,000K
Net loss
-$92,000K
(65.42%↑ Y/Y)
Accounts receivable
$62,000K
(2292.90%↑ Y/Y)
Non-cash royalty revenue
$35,000K
(-29.30%↓ Y/Y)
Other
$5,000K
(106.61%↑ Y/Y)
Inventory
$3,000K
(440.54%↑ Y/Y)
Buy us a coffee